Administration of N-acetylcysteine, particularly by aerosol, can at the beginning of treatment, liquefy the bronchial secretions and simultaneously increase the volume. If patient is unable to properly expectorate, it is necessary to clear the airways by postural drainage or eventually by bronchosuction to avoid retention of secretions.
Patients suffering from bronchial asthma must be closely monitored as bronchospasm may occur during the treatment. In such event the treatment must be immediately suspended.
N-acetylcysteine aerosol may worsen cough in patients suffering from acute bronchial asthma.
A sulphur odour is felt on opening the ampoules or transferred to the aerosol equipment, may assume a pink colour, but it does not affect the efficacy and safety of the product.